Office Of Combination Products Keeps Up Work To Clarify Regulatory Process
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of Combination Products says it is working hard to provide industry with a clearer framework for bringing technologies that unite drugs, devices and biologics to market